Trevi Therapeutics Inc (Nasdaq: TRVI), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Margaret Garin, MD, MSCR, as its new vice president of Clinical Development.
In the new role, Dr Garin will be responsible for advancing the clinical development of the company's Haduvio in chronic cough.
Dr Garin has more than 14 years of industry and academic research experience and more than nine years of global pharmaceutical industry experience in early and late-stage development. She has served as the executive director of Clinical Development at Bellus Health (now owned by GSK). She was the clinical development lead for programs in respiratory and inflammation at Teva Pharmaceuticals.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial